Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, ≥18 years of age
CHC infection, genotype 1
Hepatitis C virus (HCV) RNA ≥400,000 IU/mL
Baseline body weight ≥85 kg
Liver biopsy (within 24 months of first dose) with results consistent with CHC
You may not be if
Previous treatment with interferon, ribavirin, viramidine, levovirin, HCV polymerase or protease inhibitors
Other forms of liver disease, including liver cancer
Human immunodeficiency virus infection
Clareo Health | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
